The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Modernization and supply chain diversity drive new growth
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
Total investment incurred for setting up the new R&D Rs 250 crore
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Subscribe To Our Newsletter & Stay Updated
